Healthcare -
Biotechnology - NASDAQ - DE
$ 3.47
-3.17 %
$ 781 M
Market Cap
6.59
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CureVac N.V.
| Net Income | 191 M |
| Depreciation & Amortization | 18.8 M |
| Capital Expenditures | -18.4 M |
| Stock-Based Compensation | 4.12 M |
| Change in Working Capital | -164 M |
| Others | 16.6 M |
| Free Cash Flow | 83.4 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | 190.9 | (260.2) | (249.2) | (412.5) | (129.8) | (100.1) | (71.1) |
| Depreciation & Amortization | 18.8 | 23.4 | 23.7 | 15.7 | 10.7 | 7.2 | 3.8 |
| Deferred Income Tax | 0 | 0 | (1.6) | 199.0 | (2.9) | (0.8) | 52 K |
| Stock Based Compensation | 4.1 | 7.7 | 9.2 | 15.0 | 14.2 | 19.6 | (4.2) |
| Other Operating Activities | 52.0 | 29.5 | 57.2 | (480.7) | 51.6 | 9.9 | (1.5) |
| Change in Working Capital | (164.0) | (68.3) | (125.6) | (69.5) | 578.6 | (22.7) | (1.1) |
| Cash From Operations | 101.9 | (267.9) | (286.2) | (733.1) | 522.4 | (87.0) | (74.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (18.4) | (55.2) | (93.2) | (127.9) | (47.4) | (12.2) | (14.7) |
| Other Items | 0 | 0 | (0.3) | 0 | 2.1 | 40.4 | 10.5 |
| Cash From Investing Activities | (18.4) | (55.2) | (93.5) | (127.9) | (45.3) | 28.2 | (4.3) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | (30.9) | 0 | 0 | 0 |
| Total Debt Repaid | (5.1) | (5.2) | (4.2) | (28.2) | (47.9) | 68.0 | (0.1) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 |
| Cash From Financing Activities | (5.1) | 230.9 | 63.2 | 345.0 | 819.8 | 68.0 | (0.1) |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 79.3 | (93.3) | (315.7) | (511.1) | 1 291.9 | 9.3 | (78.3) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | 83.4 | (323.1) | (379.4) | (861.0) | 475.1 | (99.2) | (88.8) |